Skip to main content
. 2020 Sep 4;7:581828. doi: 10.3389/fmolb.2020.581828

FIGURE 2.

FIGURE 2

Comparison of FVC (A) and DLCO (B) decrease rate between pirfenidone and nintedanib subgroup (*p = 0.0201).